Recursion Pharmaceuticals (NASDAQ:RXRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:58 AM.
Here’s what investors need to know about the announcement.
Earnings
Recursion Pharmaceuticals missed estimated earnings by 13.16%, reporting an EPS of $-0.43 versus an estimate of $-0.38.
Revenue was down $2.63 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 5.02% drop in the share price the next day.
Here’s a look at Recursion Pharmaceuticals’s past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.37 | -0.35 | -0.29 | -0.38 |
| EPS Actual | -0.38 | -0.34 | -0.31 | -0.35 |
| Revenue Estimate | 11.91M | 14.44M | 24.00M | 6.97M |
| Revenue Actual | 11.02M | 12.13M | 13.68M | 13.16M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for Recursion Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
